World’s first Intranasal Vaccine iNCOVACC has received approval for Covid booster doses from Drugs Controller General of India (DCGI).
Bharat Biotech’s intranasal Covid-19 vaccine iNCOVACC has received the Indian drug regulator’s nod to be used as a heterologous booster.
iNCOVACC has got approval for restricted use in emergency situations on those aged 18 years and above, for heterologous booster after two doses of either Covishield or Covaxin.
It is the world's first intranasal vaccine to receive both primary series and heterologous booster approval.
iNCOVACC is a chimpanzee adenovirus-based vectored recombinant nasal vaccine that has been specifically formulated to allow intranasal delivery through nasal drops.
This nasal vaccine becomes the second-approved Covid-19 vaccine in India, after Biological E’s Corbevax, which can be used as a mix-and-match booster shot.
